Privileged Scaffolds in Drug Discovery

Bin Yu · Ning Li · Caiyun Fu

2023年7月 · Elsevier

電子書

850

頁

符合資格

評分和評論未經驗證瞭解詳情

關於本電子書

Privileged Scaffolds in Drug Discovery is the most complete and up-to-date work in the area. Covering a wide range of privileged structures, it is a perfect reference for scientists involved in targeted drug development. The editors recruited epserts from several prestigious Chinese institutions to cover the areas of antiviral drugs, chalcone, pyrimidine, (benz)imidazoles, natural product-derived privileged scaffolds, N-Sulfonyl carboxamides, kinase inhibitors, antitumor molecules, antineurodegenerative drugs, triazoles, oxazolidinone, indole and indoline scaffolds, tigliane diterpenoids, peptide and peptide-based drugs, quassinoids, and others including pseudonatural products, macrocycles, stable peptides and peptidomimetics. The book also explores scaffolds in drug molecules approved in recent years. Privileged Scaffolds in Drug Discovery is a complete reference for researchers in drug discovery and organic synthesis, in academic and corporate settings, who are investigating privileged structures upon which to base new drugs. Researchers in medicinal chemistry and chemical biology will also find the contents of this book valuable. - Provides wide coverage of privileged scaffolds in new drug discovery - Includes complex and diverse natural product scaffolds - Covers applications to peptides and peptide-based drugs

關於作者

Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10.

Professor Ning Li is the associate dean of Chinese Materia Medica of Shenyang Pharmaceutical University, the "Youth talent" of Liao Ning Revitalization Talents Program, the "Talent of Hundred level" of Liaoning Bai Qian Wan Talents Program, the "Leading talent" of both Shenyang High-Level Talent Program and Xinjiang Uygur Autonomous Region. She has focused on the research of chemoprevention of critical diseases, especially the neurodegenerative disease and cancer, through post-transcriptional mechanism on the perspective view of ‘preventive treatment strategy’ of the Traditional Chinese theory. She has hosted seven projects of National Natural Science Foundation of China and published more than 120 SCI papers on famous academic journals, born several prizes like the "First Prize of Provincial Science and technology progress award", and obtained the authorization of 20 invention patents.

Professor Caiyun Fu obtained her PhD degree from Lanzhou university and currently is a professor of biology and deputy director of the College of Life Sciences and Medicine, director of the Research Institute for Polypeptide and Protein Pharmaceutical Products, Zhejiang Sci-Tech University. Her research interests focus on screening and identification of tumor targets and exploration of targeted intervention and developing new drugs of peptides by synthetic biology. To date she has published 34 academic papers as corresponding author or first author in international high-impact peer-reviewed journals, including Proceedings of the National Academy of Sciences of the United States of America, Advanced Science, Journal of the American Chemical Society, Angewandte Chemie International Edition, Signal Transduction and Targeted Therapy, etc